vs

Side-by-side financial comparison of Phathom Pharmaceuticals, Inc. (PHAT) and Riley Exploration Permian, Inc. (REPX). Click either name above to swap in a different company.

Riley Exploration Permian, Inc. is the larger business by last-quarter revenue ($97.3M vs $57.6M, roughly 1.7× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs -5.3%).

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.

Riley Exploration Permian, Inc. is an independent energy company focused on exploration, development, and production of crude oil, natural gas, and natural gas liquids primarily in the US Permian Basin spanning Texas and New Mexico. It prioritizes cost-efficient onshore reserve development to supply reliable energy products to North American markets.

PHAT vs REPX — Head-to-Head

Bigger by revenue
REPX
REPX
1.7× larger
REPX
$97.3M
$57.6M
PHAT
Growing faster (revenue YoY)
PHAT
PHAT
+99.4% gap
PHAT
94.1%
-5.3%
REPX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
PHAT
PHAT
REPX
REPX
Revenue
$57.6M
$97.3M
Net Profit
Gross Margin
86.7%
Operating Margin
26.9%
Net Margin
Revenue YoY
94.1%
-5.3%
Net Profit YoY
71.6%
EPS (diluted)
$4.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PHAT
PHAT
REPX
REPX
Q4 25
$57.6M
$97.3M
Q3 25
$49.5M
$106.9M
Q2 25
$39.5M
$85.4M
Q1 25
$28.5M
$102.5M
Q4 24
$29.7M
$102.7M
Q3 24
$16.4M
$102.3M
Q2 24
$7.3M
$105.4M
Q1 24
$99.7M
Net Profit
PHAT
PHAT
REPX
REPX
Q4 25
Q3 25
$-30.0M
$16.3M
Q2 25
$-75.8M
$30.5M
Q1 25
$-94.3M
$28.6M
Q4 24
Q3 24
$-85.6M
$25.7M
Q2 24
$-91.4M
$33.5M
Q1 24
$18.8M
Gross Margin
PHAT
PHAT
REPX
REPX
Q4 25
86.7%
Q3 25
87.5%
Q2 25
87.2%
Q1 25
86.9%
Q4 24
87.1%
Q3 24
85.6%
Q2 24
81.2%
Q1 24
Operating Margin
PHAT
PHAT
REPX
REPX
Q4 25
26.9%
Q3 25
-30.8%
27.0%
Q2 25
-151.7%
33.7%
Q1 25
-276.5%
48.3%
Q4 24
31.2%
Q3 24
-433.0%
17.1%
Q2 24
-1055.4%
50.9%
Q1 24
50.7%
Net Margin
PHAT
PHAT
REPX
REPX
Q4 25
Q3 25
-60.5%
15.3%
Q2 25
-191.9%
35.7%
Q1 25
-330.7%
27.9%
Q4 24
Q3 24
-523.3%
25.1%
Q2 24
-1248.6%
31.8%
Q1 24
18.8%
EPS (diluted)
PHAT
PHAT
REPX
REPX
Q4 25
$4.02
Q3 25
$-0.41
$0.77
Q2 25
$-1.05
$1.44
Q1 25
$-1.31
$1.36
Q4 24
$0.52
Q3 24
$-1.32
$1.21
Q2 24
$-1.56
$1.59
Q1 24
$0.94

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PHAT
PHAT
REPX
REPX
Cash + ST InvestmentsLiquidity on hand
$130.0M
Total DebtLower is stronger
$209.1M
$247.9M
Stockholders' EquityBook value
$-438.2M
$634.2M
Total Assets
$259.1M
$1.2B
Debt / EquityLower = less leverage
0.39×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PHAT
PHAT
REPX
REPX
Q4 25
$130.0M
Q3 25
$135.2M
Q2 25
$149.6M
Q1 25
$212.3M
Q4 24
$297.3M
Q3 24
$334.7M
Q2 24
$276.2M
Q1 24
Total Debt
PHAT
PHAT
REPX
REPX
Q4 25
$209.1M
$247.9M
Q3 25
$207.1M
$367.0M
Q2 25
$205.1M
$275.2M
Q1 25
$203.2M
$249.3M
Q4 24
$201.4M
$269.5M
Q3 24
$175.7M
$288.6M
Q2 24
$174.4M
$322.7M
Q1 24
$341.8M
Stockholders' Equity
PHAT
PHAT
REPX
REPX
Q4 25
$-438.2M
$634.2M
Q3 25
$-422.5M
$566.5M
Q2 25
$-405.8M
$556.9M
Q1 25
$-338.4M
$532.4M
Q4 24
$-253.6M
$510.6M
Q3 24
$-187.1M
$507.4M
Q2 24
$-233.8M
$489.0M
Q1 24
$434.6M
Total Assets
PHAT
PHAT
REPX
REPX
Q4 25
$259.1M
$1.2B
Q3 25
$240.3M
$1.2B
Q2 25
$250.2M
$1.0B
Q1 25
$294.2M
$994.9M
Q4 24
$378.3M
$993.5M
Q3 24
$387.0M
$997.9M
Q2 24
$319.4M
$1.0B
Q1 24
$956.4M
Debt / Equity
PHAT
PHAT
REPX
REPX
Q4 25
0.39×
Q3 25
0.65×
Q2 25
0.49×
Q1 25
0.47×
Q4 24
0.53×
Q3 24
0.57×
Q2 24
0.66×
Q1 24
0.79×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PHAT
PHAT
REPX
REPX
Operating Cash FlowLast quarter
$-166.8M
$64.9M
Free Cash FlowOCF − Capex
$-167.0M
FCF MarginFCF / Revenue
-290.0%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-328.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PHAT
PHAT
REPX
REPX
Q4 25
$-166.8M
$64.9M
Q3 25
$-14.1M
$63.6M
Q2 25
$-62.7M
$33.6M
Q1 25
$-84.9M
$50.4M
Q4 24
$-266.8M
$66.4M
Q3 24
$-63.6M
$72.1M
Q2 24
$-70.7M
$51.6M
Q1 24
$56.1M
Free Cash Flow
PHAT
PHAT
REPX
REPX
Q4 25
$-167.0M
Q3 25
$-14.1M
Q2 25
$-62.8M
Q1 25
$-84.9M
Q4 24
$-266.9M
Q3 24
$-63.6M
Q2 24
$-70.8M
Q1 24
FCF Margin
PHAT
PHAT
REPX
REPX
Q4 25
-290.0%
Q3 25
-28.6%
Q2 25
-159.0%
Q1 25
-297.9%
Q4 24
-899.8%
Q3 24
-389.0%
Q2 24
-966.2%
Q1 24
Capex Intensity
PHAT
PHAT
REPX
REPX
Q4 25
0.4%
Q3 25
0.1%
Q2 25
0.2%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.3%
Q2 24
0.6%
Q1 24
Cash Conversion
PHAT
PHAT
REPX
REPX
Q4 25
Q3 25
3.90×
Q2 25
1.10×
Q1 25
1.76×
Q4 24
Q3 24
2.81×
Q2 24
1.54×
Q1 24
2.99×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons